Author

Ilya Folitar

Observed names: I. Folitar, Ilia Folitar, MD Ilya Folitar,

Observed institutions: F. Hoffmann-La Roche AG, Novartis (Switzerland)

ORCID: 0000-0002-1399-0504

Observed ORCID: 0000-0002-1399-0504

OpenAlex ID: A5081616504

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

2024 · Simron Singh, Daniel Halperin, et al. · The Lancet · 397

[ 177 Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study.

2024 · Simron Singh, Daniel M. Halperin, et al. · Journal of Clinical Oncology · 46

PDF

Efficacy and safety of 177Lu‑DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study

2022 · Dominique Clement, Shaunak Navalkissoor, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 29

PDF

Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Adults with Inoperable or Metastatic Somatostatin Receptor-Positive Pheochromocytomas/Paragangliomas, Bronchial and Unknown Origin Neuroendocrine Tumors, and Medullary Thyroid Carcinoma: A Systematic Literature Review

2023 · Marianna Hertelendi, Oulaya Belguenani, et al. · Biomedicines · 12

PDF

[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study

2024 · Diego Ferone, Daniel Halperin, et al. · Endocrine Abstracts · 10

211MO First-line efficacy of [177Lu]Lu-DOTA-TATE in patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: Subgroup analysis of the phase III NETTER-2 study

2024 · S. Singh, D. Halperin, et al. · Annals of Oncology · 9

PDF

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers

2021 · Joseph F. Grippo, Ilia Folitar, et al. · Clinical and Translational Science · 8

PDF

Efficacy and safety of 177Lu-DOTATATE in patients (pts) with advanced pancreatic neuroendocrine tumors (pNETs): Data from the NETTER-R international, retrospective registry.

2021 · Dominique Clement, Shaunak Navalkissoor, et al. · Journal of Clinical Oncology · 5

RO7020531, a novel prodrug of a toll-like receptor 7 agonist, is safe, well tolerated and activates TLR signaling in healthy volunteers

2018 · E. Gane, I. Folitar, et al. · Journal of Hepatology · 5

Safety and time to response of [177Lu]Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study.

2024 · Pamela L. Kunz, Diego Ferone, et al. · Journal of Clinical Oncology · 2

EP14.01-020 Trial in Progress: [177Lu]Lu-DOTA-TATE Combination Therapy in Treatment-Naïve Extensive Stage Small Cell Lung Cancer

2022 · S. Liu, D. Planchard, et al. · Journal of Thoracic Oncology · 2

PDF

Matching adjusted indirect comparison (MAIC) of 177 Lu-DOTATATE vs. sunitinib as first-line (1L) treatment for advanced grade 2 (G2) pancreatic neuroendocrine tumors (pNETs).

2025 · Raj Srirajaskanthan, Jaume Capdevila, et al. · Journal of Clinical Oncology · 1

PDF

Protocol for a systematic literature review of efficacy and safety of [177Lu]Lu-DOTA-TATE in adults with inoperable or metastatic somatostatin receptor-positive pheochromocytomas/paragangliomas, bronchial and unknown origin neuroendocrine tumors, and medullary thyroid carcinoma

2023 · Advanced Accelerator Applications International SA, Geneva, Switzerland, Marianna Hertelendi, et al. · 1

PDF

92: [177Lu]Lu-Dota-Tate as First-Line Therapy for Patients with Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETS): The NETTER-2 Study

2022 · Sten Myrehaug, Simron Singh, et al. · Radiotherapy and Oncology · 1

TLR7 agonist ro7020531 triggers immune activation after multiple doses in chronic hepatitis B patients

2018 · E. Gane, K Agarwai, et al. · 1

[177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2–3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial

2026 · Diego Ferone, Marianne Pavel, et al. · EClinicalMedicine

First-line efficacy of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: phase 3 NETTER-2 subgroup analysis

2025 · MD Simron Singh,, MD Daniel Halperin,, et al. · Endocrine Abstracts

[177Lu]Lu-DOTA-TATE chez les patients nouvellement diagnostiqués atteints de TNE GEP avancées bien différenciées de grade (G)2 et 3 : analyse primaire de NETTER-2

2025 · S. Singh, D. Halperin, et al. · Médecine Nucléaire

A systematic literature review of studies assessing first-line (1L) treatments in patients with advanced, grade 2/3 (G2/G3) gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

2025 · Jaume Capdevila, Emmanuel Deshayes, et al. · Journal of Clinical Oncology

PDF

1148MO A multivariate efficacy analysis of [177Lu]Lu-DOTA-TATE in the NETTER 2 study

2024 · M.E. Pavel, D. Ferone, et al. · Annals of Oncology

PDF

1122TiP A phase II trial to evaluate the safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), pheochromocytomas and paragangliomas (PPGLs)

2021 · M.N. Gaze, M.S. O'Dorisio, et al. · Annals of Oncology

Works count: 21

Citation count: 528

H-index: 7

I10-index: 5